EHMT2 and brain neoplasm: Further research should increase our understanding by focusing on identifying the possible differential sensitivities of distinct brain tumor molecular subgroups and subtypes to G9a inhibition, as well as comparing different available inhibitors, including dual inhibitors, in brain tumor models, in addition to evaluating combinations of G9a inhibitors with other epigenetic or non-epigenetic anticancer agents.